Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2013. The report details a specific share repurchase transaction executed on September 12, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,230,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,633.50 pence per share; lowest price paid was 1,618.50 pence per share.
- Treasury Holdings (Settled): 517,760,412 shares (9.56% of total issued share capital).
- Treasury Holdings (Including Unsettled): 520,172,412 shares (10.62% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,896,213,094 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,230,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.62% when including unsettled purchases. The filing does not provide comparative data for prior periods regarding these specific metrics.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (517,760,412 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.56% Treasury ownership calculation.
- Check the status of the 2,412,000 shares purchased but not yet settled to determine if they have been finalized.
- Review the remaining authorization for share buybacks under the mandate granted on May 1, 2013.